Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study

Shares of Moderna traded 23% higher after the company reported that it has developed and shipped a mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. Yesterday evening, clinical stage biotechnology company Moderna Inc. (MR...

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. Analyst Ram Selvaraju reported in a July 8 research note that H.C. Wainwright & Co. initiated coverage on Replimune Group Inc. (REPL:NASDAQ) with a Buy ...